Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.06
+0.20 (1.44%)
Feb 21, 2025, 4:00 PM EST - Market closed
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
$590,997
Profits / Employee
$26,854
Market Cap
44.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
TAK News
- 22 days ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha
- 22 days ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge - Business Wire
- 23 days ago - Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 - Business Wire
- 23 days ago - Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates - Reuters
- 23 days ago - Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth - Business Wire
- 4 weeks ago - Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO - Reuters
- 4 weeks ago - Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO - Reuters